Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01528514

Acronym

CUPID

Enrollment

200

Registered

2012-02-08

Start date

2009-09-30

Completion date

2012-12-31

Last updated

2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass Grafting

Keywords

Myocardial infarction, Coronary artery bypass grafting, Anti-oxidant, Curcuminoids

Brief summary

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

Interventions

OTHERPlacebo

Placebo in capsule form, 4 capsules 4 times/day

DIETARY_SUPPLEMENTCurcuminoids

Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patients undergoing CABG without valve surgery

Exclusion criteria

* emergency cardiac surgery * any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization * patients with cholestatic jaundice (total bilirubin \> 2-fold ULN) * severe liver disease (AST or ALT \> 3-fold ULN)

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative myocardial infarction	participants will be followed for the duration of hospital stay, an expected average of 10 days

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026